# M.D. Anderson Cancer Center: Phase 1 study closed enrollment, 10 enrolled (Colorectal Cancer, Minimal Residual Disease)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | M.D. Anderson Cancer Center |
| Sponsor type | Academic and hospital |
| Study | Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) |
| NCT ID | NCT06358430 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Colorectal Cancer; Minimal Residual Disease |
| Intervention types | drug, procedure |
| Target enrollment | 10 |
| Site countries | United States |
| Posted | 2024-04-10 |
| Planned start | 2024-12-02 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-03 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06358430). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.